News

September 16, 2015 9:45 am
Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for daratumumab as a treatment for patients with multiple myeloma...
September 16, 2015 9:15 am
A group of physicians from leading medical institutions in China came to Los Angeles to learn about myeloma during the International Myeloma Foundation’s recent Myeloma Master Class. In his blog this week, IMF Chairman Dr. Brian Durie, details some...
September 14, 2015 11:45 am
The IMF has been awarded Charity Navigator’s 4-star, highest rating for 2014! The rating, according to Charity Navigator, indicates that the IMF operates in an ethical and fiscally responsible manner. A 4-star rating is the highest rating a charity...
September 2, 2015 9:45 am
A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the...

Pages